000			02164 a2200589 4500
005			20250517160425.0
264		0	_c20170926
008			201709s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2017.05.028 _2doi
040			_aNLM _beng _cNLM
100	1		_aGao, Fei
245	0	0	_aSuppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis. _h[electronic resource]
260			_bCancer letters _c08 2017
300			_a177-189 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Movement _xdrug effects
650	0	4	_aDown-Regulation
650	0	4	_aEpithelial-Mesenchymal Transition _xdrug effects
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aGenetic Predisposition to Disease
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Knockout
650	0	4	_aMice, Nude
650	0	4	_aPhenotype
650	0	4	_aProstatic Neoplasms _xdrug therapy
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProtein Serine-Threonine Kinases _xmetabolism
650	0	4	_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors
650	0	4	_aRNA Interference
650	0	4	_aReceptor, Transforming Growth Factor-beta Type II
650	0	4	_aReceptors, Transforming Growth Factor beta _xmetabolism
650	0	4	_aSignal Transduction
650	0	4	_aTime Factors
650	0	4	_aTransfection
650	0	4	_aTransforming Growth Factor beta1 _xmetabolism
650	0	4	_aXenograft Model Antitumor Assays
650	0	4	_abeta Catenin _xantagonists & inhibitors
700	1		_aAlwhaibi, Abdulrahman
700	1		_aSabbineni, Harika
700	1		_aVerma, Arti
700	1		_aEldahshan, Wael
700	1		_aSomanath, Payaningal R
773	0		_tCancer letters _gvol. 402 _gp. 177-189
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2017.05.028 _zAvailable from publisher's website
999			_c27266612 _d27266612